Medizinische Universität Graz - Research portal
Selected Publication:
Jäger, G; Neumeister, P; Brezinschek, R; Hinterleitner, T; Fiebiger, W; Penz, M; Neumann, HJ; Mlineritsch, B; DeSantis, M; Quehenberger, F; Chott, A; Beham-Schmid, C; Höfler, G; Linkesch, W; Raderer, M.
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.
J Clin Oncol. 2002; 20(18):3872-3877
Doi: 10.1200/JCO.2002.05.117
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Jaeger Gerald
- Co-authors Med Uni Graz
- Beham-Schmid Christine
- Hinterleitner Thomas
- Höfler Gerald
- Linkesch Werner
- Neumeister Peter
- Quehenberger Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- As chemotherapy has not been extensively studied in patients with lymphoma of the mucosa-associated lymphoid tissue (MALT), we initiated a prospective study to evaluate the activity of the nucleoside analog cladribine (2-chlorodeoxyadenosine [2-CdA]) in this disease. Patients with histologically verified MALT-type lymphoma were enrolled. 2-CdA was administered at a dose of 0.12 mg/kg body weight on 5 consecutive days, as a 2-hour infusion. Cycles were repeated every 4 weeks for a maximum of six cycles. Nineteen patients with gastric and seven patients with extragastric MALT lymphoma were enrolled. All patients were chemotherapy-naive, and two had been locally irradiated before systemic relapse of the lymphoma. A total of 102 cycles was administered to our patients (median number of cycles per patient, four). All 25 assessable patients responded to treatment: 21 patients (84%) achieved complete remission (CR) and four patients achieved partial remission. All patients (100%) with gastric presentation, but only three patients (43%) with extragastric presentation, achieved CR. Toxicities were moderate and mainly hematologic and required dose reduction and/or premature discontinuation of therapy in only three cases. Two patients died from vascular events, one shortly after the first cycle because of myocardial infarction and the other from stroke 3 months after the second course. Three patients relapsed after 13, 18, and 22 months and one patient showed progressive disease after 15 months. At present, 24 patients are alive at a median follow-up time of 32 months. Our data demonstrate that 2-CdA is highly effective in inducing CR in 84% of patients with MALT-type lymphoma.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Agents - adverse effects
- Antineoplastic Agents - therapeutic use
- B-Lymphocytes -
- Cladribine - adverse effects
- Cladribine - therapeutic use
- Disease-Free Survival -
- Female -
- Follow-Up Studies -
- Humans -
- Lacrimal Apparatus - pathology
- Liver - pathology
- Lymphoid Tissue - drug effects
- Lymphoid Tissue - pathology
- Lymphoma, B-Cell, Marginal Zone - drug therapy
- Lymphoma, B-Cell, Marginal Zone - pathology
- Male -
- Middle Aged -
- Neoplasm Staging -
- Parotid Gland - pathology
- Prospective Studies -
- Remission Induction -
- Stomach Neoplasms - drug therapy
- Stomach Neoplasms - pathology
- Survival Rate -